Methotrexate vs Hydroxychloroquine

Methotrexate is the most effective conventional DMARD for rheumatoid arthritis. It significantly reduces joint inflammation, slows joint damage, and improves physical function. Clinical trials show ACR20 response rates (20% improvement) of 50-65% with methotrexate monotherapy. It is the standard against which all other RA treatments are compared.

Hydroxychloroquine is less potent than methotrexate as monotherapy. It is most effective for mild RA or as part of combination DMARD therapy. The ACR20 response rate with hydroxychloroquine alone is approximately 30-40%. However, adding hydroxychloroquine to methotrexate can provide additional benefit.

Hydroxychloroquine is also used for systemic lupus erythematosus, where it is considered a cornerstone treatment. It has modest benefits for joint pain and fatigue.

Methotrexate requires regular blood monitoring (every 1-3 months) for liver function, kidney function, and blood counts. Common side effects include nausea, mouth sores, fatigue, and hair thinning. Serious risks include liver damage, bone marrow suppression, and lung toxicity. Folic acid supplementation (1 mg daily) is routinely prescribed with methotrexate to reduce side effects. Methotrexate is strictly contraindicated in pregnancy due to teratogenicity.

Hydroxychloroquine has a notably better safety profile. Common side effects are mild and include nausea, diarrhea, and headache. The most important long-term risk is retinal toxicity (damage to the retina), which can occur after years of use — annual eye exams are recommended after 5 years of treatment (or sooner with risk factors). Blood monitoring is less intensive than with methotrexate.

Hydroxychloroquine is generally considered safer for women of childbearing age and may be continued during pregnancy in certain situations under medical supervision.

Both medications are available as affordable generics. Methotrexate costs approximately $10-$30 per month for oral tablets. Hydroxychloroquine costs approximately $15-$40 per month. Both are among the most cost-effective treatments for RA.

The monitoring costs differ: methotrexate requires regular blood tests ($50-$200 per visit) and periodic liver assessment. Hydroxychloroquine requires annual ophthalmology exams ($100-$300).

Methotrexate is typically taken once weekly (oral tablets or subcutaneous injection), not daily. Many patients take it on the same day each week. Weekly dosing reduces side effects compared to daily dosing. Subcutaneous injection can improve efficacy and reduce GI side effects for some patients.

Hydroxychloroquine is taken once or twice daily by mouth. It is simpler in terms of monitoring but requires daily compliance rather than weekly.

For moderate to severe rheumatoid arthritis, methotrexate is typically the first DMARD prescribed. Its proven efficacy in slowing joint damage makes it the standard of care. If you can tolerate the monitoring requirements and are not planning pregnancy, methotrexate is usually the best starting choice.

Hydroxychloroquine may be appropriate as initial therapy for very mild RA, or if methotrexate is contraindicated (pregnancy, liver disease, significant kidney impairment). It is often added to methotrexate in combination therapy for patients who need additional disease control.

Many patients ultimately use both drugs together. Your rheumatologist will tailor treatment to your disease severity, other health conditions, and life circumstances.